Results 131 to 140 of about 42,840 (198)

Pre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry

ESC Heart Failure, EarlyView.
Among 668 with cardiogenic shock included in the multicentre prospective Altshock‐2 registry, 299 patients (44.8%) received pre‐admission beta‐blocker therapy. Previous beta‐blocker therapy influenced the early hemodynamic response to vasoactive drugs, but it was not associated with in‐hospital mortality.
Matteo Pagnesi, Mauro Riccardi, Alice Sacco, Giovanni Tavecchia, Giovanna Viola, Simone Frea, Martina Briani, Letizia Fausta Bertoldi, Maurizio Bertaina, Luciano Potena, Serafina Valente, Marco Marini, Gaetano Maria De Ferrari, Nicoletta D'Ettore, Astrid Cardinale, Rita Camporotondo, Matteo Rota, Guido Tavazzi, Nuccia Morici, Federico Pappalardo, Marco Metra, on behalf of the Altshock‐2 investigators   +21 more
wiley   +1 more source

Multi‐microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome accounting for half of heart failure cases. Although natriuretic peptides are the most accepted and extensively used biomarkers for heart failure, their diagnostic accuracy for HFpEF remains debatable.
Reza Parvan, Natale Rolim, Andreas B. Gevaert, Alessandro Cataliotti, Emeline M. van Craenenbroeck, Volker Adams, Ulrik Wisløff, Gustavo Jose Justo Silva, on behalf of the OptimEx Study Group   +8 more
wiley   +1 more source

Left ventricular decompression in paediatric veno‐arterial extracorporeal life support: Reviewing the evidence

ESC Heart Failure, EarlyView.
Abstract Veno‐arterial extracorporeal life support (VA ECLS) is crucial for neonatal and paediatric patients with severe circulatory collapse but may cause left ventricular (LV) overload, affecting myocardial recovery and causing complications. Evidence on optimal LV decompression strategies in paediatric patients remains limited.
Giacomo Veronese, Paolo Meani, Domenico Sirico, Giovanni Di Salvo, Enrico Ammirati, Alessandro Varrica, Umberto Di Dedda, Paolo Bianchi, Giuseppe Isgrò, Alessandro Giamberti, Tommaso Aloisio, Marc Dickstein, Ezio Bonanomi, Bahaaldin Alsoufi, Ravi R. Thiagarajan, Peta M.A. Alexander, D. Michael McMullan, Ryan P. Barbaro, Graeme MacLaren, Marco Ranucci, Navin K. Kapur, Roberto Lorusso   +21 more
wiley   +1 more source

Short report: Hospitalization for new‐onset heart failure in survivors of hospitalized COVID‐19

ESC Heart Failure, EarlyView.
Abstract Aims Previous studies have reported an incidence of new‐onset heart failure (HF) among COVID‐19 survivors ranging from 0.7 to 8.5 per 100 person‐years, but they relied on administrative data for outcome ascertainment. Given the public health implications, a more accurate characterization of the HF burden post‐COVID‐19 is important. Methods and
Vicente Corrales‐Medina, Jordana B. Cohen, Seavmeiyin Kun, Bianca Pourmussa, Ozgun Erten, Joe‐David Azzo, Julio A. Chirinos   +6 more
wiley   +1 more source

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients

ESC Heart Failure, EarlyView.
Abstract Aims The study aimed to assess whether the effect of nutritional risk score (NRS‐2002) on the odds of in‐hospital mortality would be modulated by sex and body mass index (BMI) in patients with heart failure with preserved ejection fraction (HFpEF).
Michał Czapla, Adrian Kwaśny, Izabella Uchmanowicz, Łukasz Pietrzykowski, Christopher S. Lee, Wojciech Kosowski, Stanisław Surma, Halina Grajeta, Łukasz Lewandowski   +8 more
wiley   +1 more source

New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB. [PDF]

Mol Oncol
Haase A, Miroschnikov N, Klein S, Doege A, Dünker N, Van Meenen D, Junker A, Göpferich A, Apaolaza PS, Busch MA.   +9 more
europepmc   +1 more source

Atrial natriuretic peptide signaling co-regulates lipid metabolism and ventricular conduction system gene expression in the embryonic heart. [PDF]

iScience
Mishra A, Tavasoli M, Sokolenko S, McMaster CR, Pasumarthi KBS.   +4 more
europepmc   +1 more source

Implementation of guidelines for intravenous iron therapy in heart failure patients

ESC Heart Failure, EarlyView.
Abstract Aims We aim to evaluate the implementation of the 2021 ESC Guidelines regarding screening and treatment of iron deficiency in patients with heart failure (HF) at Karolinska University Hospital. Methods and results Patients with left ventricular ejection fraction (LVEF) < 50% and New York Heart Association (NYHA) class II–IV who visited ...
Milou Gamage, Aristomenis Manouras, Camilla Hage, Gianluigi Savarese, Karin Ljung, Michael Melin   +5 more
wiley   +1 more source

Identification, characterisation and outcomes of pre‐atrial fibrillation in heart failure with reduced ejection fraction

ESC Heart Failure, EarlyView.
Abstract Aims Atrial fibrillation (AF) in heart failure with reduced ejection fraction (HFrEF) has prognostic implications. Using a machine learning algorithm (FIND‐AF), we aimed to explore clinical events and the cardiac magnetic resonance (CMR) characteristics of the pre‐AF phenotype in HFrEF.
Anna Helbitz, Ramesh Nadarajah, Lan Mu, Harriet Larvin, Hesham Ismail, Ali Wahab, Patrick Thompson, Peter Harrison, Mohammad Harris, Tobin Joseph, Sven Plein, Mark Petrie, Marco Metra, Jianhua Wu, Peter Swoboda, Chris P. Gale   +15 more
wiley   +1 more source

Furosemide‐hydration matching with RenalGuard® in decompensated heart failure: an alternative way to use diuretics and saline

ESC Heart Failure, EarlyView.
Massimo Mapelli, Filippo Maria Rubbo, Jeness Campodonico, Nicola Cosentino, Giancarlo Marenzi, Valentina Mantegazza, Filippo Trombara, Mateusz Sokolski, Piotr Ponikowski, Piergiuseppe Agostoni   +9 more
wiley   +1 more source